Telix Pharmaceuticals Ltd (TLX.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 487,021 | 338,374 | 106,116 | 3,551 | 3,598 |
| Cost of Goods | 170,088 | 128,192 | 41,877 | 1,847 | 1,556 |
| Gross Profit | 316,932 | 210,183 | 64,239 | 1,704 | 2,042 |
| Operating Expenses | 266,282 | 178,590 | 128,617 | 73,325 | 40,320 |
| Operating Income | 50,650 | 31,593 | -64,377 | -71,621 | -38,278 |
| Interest Expense | 22,691 | 9,383 | 4,553 | 3,783 | 903 |
| Other Income | 6,898 | -20,107 | 1,838 | 17,074 | 2,327 |
| Pre-tax Income | 34,857 | 2,103 | -67,093 | -58,330 | -36,855 |
| Income Tax | 3,816 | -1,447 | 3,712 | 33 | -2,343 |
| Net Income Continuous | 31,041 | 3,550 | -70,805 | -58,363 | -34,512 |
| Net Income | $31,041 | $3,550 | $-70,805 | $-58,363 | $-34,512 |
| EPS Basic Total Ops | 0.09 | 0.01 | -0.23 | -0.21 | -0.13 |
| EPS Basic Continuous Ops | 0.09 | 0.01 | -0.23 | -0.21 | -0.13 |
| EPS Diluted Total Ops | 0.09 | 0.01 | -0.23 | -0.21 | -0.13 |
| EPS Diluted Continuous Ops | 0.09 | 0.01 | -0.23 | -0.21 | -0.13 |
| EBITDA(a) | $57,548 | $11,486 | $-58,880 | $-50,797 | $-32,198 |